Millennium Management LLC increased its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 71.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,839 shares of the biopharmaceutical company's stock after purchasing an additional 80,140 shares during the period. Millennium Management LLC owned 0.39% of Theravance Biopharma worth $1,815,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Geode Capital Management LLC grew its position in shares of Theravance Biopharma by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after purchasing an additional 4,823 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in Theravance Biopharma by 9.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company's stock valued at $7,847,000 after acquiring an additional 69,178 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares during the last quarter. Bank of America Corp DE boosted its holdings in Theravance Biopharma by 2.7% in the fourth quarter. Bank of America Corp DE now owns 481,475 shares of the biopharmaceutical company's stock valued at $4,531,000 after acquiring an additional 12,596 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Theravance Biopharma by 1.6% in the fourth quarter. Northern Trust Corp now owns 389,980 shares of the biopharmaceutical company's stock valued at $3,670,000 after acquiring an additional 6,198 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company's stock.
Analysts Set New Price Targets
A number of research analysts recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of "Hold" and an average target price of $11.33.
Get Our Latest Research Report on TBPH
Insiders Place Their Bets
In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the transaction, the senior vice president now owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.90% of the stock is currently owned by insiders.
Theravance Biopharma Trading Up 4.5%
Shares of TBPH traded up $0.48 during midday trading on Friday, reaching $11.25. 295,003 shares of the company were exchanged, compared to its average volume of 275,831. The stock has a 50-day moving average price of $9.31 and a 200-day moving average price of $9.39. The company has a market cap of $562.51 million, a price-to-earnings ratio of -11.14 and a beta of -0.10. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $11.82.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. Equities research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.
About Theravance Biopharma
(
Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Further Reading
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
